Effect of proton-pump inhibitor therapy on serum chromogranin A level

Digestion

Volumn 84, Issue 1, 2011, Pages 22-28

  Pregun, István ^a   Herszényi, László ^a   Juhász, Márk ^a   Miheller, Pál ^a   Hritz, István ^a   Patócs, Attila ^a   Rácz, Károly ^a   Tulassay, Zsolt ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Acid suppression; Chromogranin A; Gastrin; Gastroesophageal reflux disease; Hypergastrinemia; Proton pump inhibitor

Indexed keywords

CHROMOGRANIN A; ESOMEPRAZOLE; GASTRIN; LANSOPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DRUG EFFICACY; DRUG MEGADOSE; ENDOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; LABORATORY TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ADULT; AGED; AGED, 80 AND OVER; CHROMOGRANIN A; FEMALE; GASTRINS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TIME FACTORS; YOUNG ADULT;

EID: 79551632075     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000321535     Document Type: Article

References (33)

1. Waldum HL, Sandvik AK, Brenna E, Petersen H: Gastrin-histamine sequence in the regulation of gastric acid secretion. Gut 1991; 32: 698-701.
2. Cui G, Waldum HL: Physiological and clinical significance of enterochromaffin-like cell activation in the regulation of gastric acid secretion. World J Gastroenterol 2007; 13: 493-496. (Pubitemid 46210913) (Pubitemid 46210913)
3. Waldum HL, Fossmark R, Bakke I, Qvigstad G: Hypergastrinemia in animals and man: causes and consequences. Scand J Gastroenterol 2004; 39: 505-509. (Pubitemid 38916252) (Pubitemid 38916252)
4. Dockray G, Dimaline R, Varro A: Gastrin: old hormone, new functions. Pflügers Arch 2005; 449: 344-355. (Pubitemid 40379124) (Pubitemid 40379124)
5. Jensen RT: Involvement of cholecystokinin/ gastrin-related peptides and their receptors in clinical gastrointestinal disorders. Pharmacol Toxicol 2002; 91: 333-350. (Pubitemid 36132438) (Pubitemid 36132438)
6. Klinkenberg-Knol EC, Festen HP, Jansen JB Lamers CB, Nelis F, Snel P, Lückers A, Dekkers CP, Havu N, Meuwissen SG: Longterm treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-167. (Pubitemid 24225631) (Pubitemid 24225631)
7. Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, Lamers C, Stockbrügger RW: Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a casecontrol study. Aliment Pharmacol Ther 1999; 13: 145-153. (Pubitemid 29090008) (Pubitemid 29090008)
8. Kim BW, Lee BI, Kim HK, Cho YS, Chae HS, Lee HK, Kim HJ, Han SW: Influence of longterm gastric acid suppression therapy on the expression of serum gastrin, chromogranin A, and ghrelin. Korean J Gastroenterol 2009; 53: 84-89.
9. Fossmark R, Jianu CS, Martinsen TC, Qvigstad G, Syversen U, Waldum HL: Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by longterm proton-pump inhibition. Scand J Gastroenterol 2008; 43: 20-24.
10. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK: Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39: 649-653. (Pubitemid 26426463) (Pubitemid 26426463)
11. Sagar M, Bertilsson L, Stridsberg M, Kjellin A, Mrdh S, Seensalu R: Omeprazole and CYP2C19 polymorphism: effects of longterm treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. Aliment Pharmacol Ther 2000; 14: 1495-1502.
12. Sanduleanu S, De Bruïne A, Stridsberg M, Jonkers D, Biemond I, Hameeteman W, Lundqvist G, Stockbrügger RW: Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 2001; 31: 802-811. (Pubitemid 34203475) (Pubitemid 34203475)
13. Taupenot L, Harper KL, O'Connor DT: The chromogranin-secretogranin family. N Engl J Med 2003; 348: 1134-1149. (Pubitemid 36337325) (Pubitemid 36337325)
14. Rao F, Keiser HR, O'Connor DT: Malignant pheochromocytoma: chromaffin granule transmitters and response to treatment. Hypertension 2000; 36: 1045-1052.
15. Sondenaa K, Sen J, Heinle F, Fjetland L, Gudlaugsson E, Syversen U: Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report. World J Surg 2004; 28: 890-895. (Pubitemid 39391893) (Pubitemid 39391893)
16. Pregun I, Gergics P, Dabasi G, Igaz P, Racz K, Tulassay Z: Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment. Eur J Gastroenterol Hepatol 2009; 21: 476-477.
17. Peracchi M, Gebbia C, Basilisco G, Quatrini M, Tarantino C, Vescarelli C, Massironi S, Conte D: Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 2005; 152: 443-448. (Pubitemid 40439498) (Pubitemid 40439498)
18. De Block CE, Colpin G, Thielemans K, Coopmans W, Bogers JJ, Pelckmans PA, Van Marck EA, Van Hoof V, Martin M, De Leeuw IH, Bouillon R, Van Gaal LF: Neuroendocrine tumor markers and enterochromaffinlike cell hyper/dysplasia in type 1 diabetes. Diabetes Care 2004; 27: 1387-1393. (Pubitemid 38679988) (Pubitemid 38679988)
19. Borch K, Stridsberg M, Burman P, Rehfeld JF: Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997; 32: 198-202. (Pubitemid 27105292) (Pubitemid 27105292)
20. Houben P., Lundqvist G, Biemond I, et al: Twenty-four hour intragastric pH, basal and meal stimulated serum gastrin, and plasma chromogranin A after short term acid inhibition. Gastroenterology 1997; 112:A152.
21. Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F: Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004; 150: 299-303. (Pubitemid 38443779) (Pubitemid 38443779)
22. Reimer C, Sondergaard B, Hilsted L, Bytzer P: Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137: 80-87.
23. Donnellan C, Sharma N, Preston C, Moayyedi P: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; 2:CD003245.
24. Zacny J, Zamakhshary M, Sketris I, Veldhuyzen van Zanten S: Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastrooesophageal reflux disease patients. Aliment Pharmacol Ther 2005; 21: 1299-1312. (Pubitemid 40813676) (Pubitemid 40813676)
25. Cremonini F, Wise J, Moayyedi P, Talley NJ: Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a meta-analysis. Am J Gastroenterol 2005; 100: 1226-1232. (Pubitemid 40904341) (Pubitemid 40904341)
26. Moayyedi P, Talley NJ: Gastro-oesophageal reflux disease. Lancet 2006; 367: 2086-2100.
27. El-Serag HB, Lau M: Temporal trends in new and recurrent oesophageal strictures in a Medicare population. Aliment Pharmacol Ther 2007; 25: 1223-1229. (Pubitemid 46650298) (Pubitemid 46650298)
28. Reimer C, Bytzer P: Clinical trial: long-term use of proton pump inhibitors in primary care patients - a cross sectional analysis of 901 patients. Aliment Pharmacol Ther 2009; 30: 725-732.
29. Pregun I, Bakucz T, Banai J, Molnár L, Pavlik G, Altorjay I, Orosz P, Csernay L, Tulassay Z, Herszényi L: Gastroesophageal reflux disease: work-related disease? Dig Dis 2009; 27: 38-44.
30. Pregun Hritz I, Tulassay Z, Herszényi L: Peptic esophageal stricture: medical treatment. Dig Dis 2009; 27: 31-37.
31. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M: Chromogranin A-biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol 2010; 17: 2427-2443.
32. Stridsberg M, Eriksson B, Oberg K, Janson ET: A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003; 177: 337-341. (Pubitemid 36656407) (Pubitemid 36656407)
33. Hirschowitz BI, Worthington J, Mohnen J, Haber M: Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia. Aliment Pharmacol Ther 2007; 26: 869-878. (Pubitemid 47346715) (Pubitemid 47346715)